SCHEMBL10194992

SCHEMBL10194992

O=S(=O)(c1ccc(-n2cc(-c3n[nH]c4ccccc34)nn2)cc1)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.48
LRRK2 Q5S007 4/20 0.45
FGFR1 P11362 2/20 0.45
FLT1 P17948 1/20 0.45
PHOSPHO1 Q8TCT1 1/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 2/20 0.44
GAA P10253 2/20 0.44
ITK Q08881 1/20 0.43
PIK3CA P42336 1/20 0.43
KDM4E B2RXH2 2/20 0.42
F2 P00734 1/20 0.42
TSHR P16473 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10194768 0.80 FLT3 (0.55) JAK2LRRK2FGFR1FLT1ITK
SCHEMBL10194970 0.80 JAK2 (0.47) JAK2LRRK2FGFR1FLT1ITK
SCHEMBL10194811 0.79 LRRK2 (0.58) LRRK2FGFR1FLT1KMT2AMEN1
SCHEMBL10194991 0.78 PTGS2 (0.46) LRRK2KMT2AMEN1KDM4E
SCHEMBL10194847 0.78 MAPT (0.47) LRRK2FGFR1FLT1ITKPIK3CA
SCHEMBL10194755 0.77 SMN1; SMN2 (0.44) JAK2LRRK2FGFR1FLT1ITK
SCHEMBL10194973 0.76 FGFR1 (0.46) LRRK2FGFR1FLT1GAAITK
SCHEMBL10194813 0.76 FKBP1A (0.49) LRRK2FGFR1FLT1KMT2AMEN1
SCHEMBL10194693 0.76 LRRK2 (0.46) LRRK2FGFR1FLT1GAAITK
SCHEMBL9952343 0.75 USP2 (0.53) LRRK2FGFR1FLT1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES NFATC1, IL5, CD4 JAK2 66/4885LRRK2 2651/4885FGFR1 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.